Another study that aims to probe the genomic landscape used liquid biopsies and circulating tumor DNA (ctDNA) obtained from prostate cancer patients and identified that AR amplification results in less responsive to antiandrogens. The gene discussed is AR; the disease is prostate carcinoma.